Last update Feb. 5, 2022

D08AH30; D09AA10; G01AC02; P01AA02; S02AA05

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Clioquinol is a halogenated hydroxyquinoline with antibacterial and antifungal properties. It is used topically in the form of creams in the treatment of skin infections and in liquid form for infections of the external ear.

At the date of the last update, there was no published data available on its excretion in human milk.

It is absorbed through the skin in an amount that could be significant, especially as an occlusive cure. (AEMPS 2008, Wilcock 1985, Stohs 1984, Fischer 1978)

Systemic clioquinol is highly neurotoxic, can cause blindness and neuropathy; it should not be used in infants. (AAP 1990)

If used, do not apply on the breast area, or in places on the maternal skin that the infant can reach, or in large areas, or as an occlusive cure or for prolonged periods to avoid increasing systemic absorption.

Alternatives

We do not have alternatives for D08AH30; D09AA10; G01AC02; P01AA02; S02AA05.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 is Clioquinol in ATC Code/s.

Is written in other languages:

D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 is also known as

Groups

D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition:

  • Bagton
  • Betnovate-C™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Bionder-C
  • Clio-Betnovate ™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Cortifung-C
  • Cuatrocrem™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Cuatroderm™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Dealan™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Diproform ™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Diproquin™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Diprosone Y ™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Ke Ai Lin (珂艾林)
  • Lasalar-Y Simple
  • Linola Sept
  • Luzolona Simple
  • Menaderm Clio™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Menaderm Otologico™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Sebryl™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Sebstopp™. Contains other elements than D08AH30; D09AA10; G01AC02; P01AA02; S02AA05 in its composition
  • Viocortil
  • Vioform
  • Vioformo

Pharmacokinetics

Variable Value Unit
Oral Bioavail. (derm: 3 a 40 ) %
Molecular weight 306 daltons
pKa 7.34 -
11 - 14 hours

References

  1. AEMPS. Menaderm otológico (Beclometasona + Clioquinol). Ficha técnica 2008 Full text (in our servers)
  2. AAP. American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics. 1990 Nov;86(5):797-8. No abstract available. Abstract Full text (link to original source)
  3. Wilcock M. Absorption of iodochlorhydroxyquin in humans. J Invest Dermatol. 1985 Jan;84(1):79. No abstract available. Abstract Full text (link to original source)
  4. Stohs SJ, Ezzedeen FW, Anderson AK, Baldwin JN, Makoid MC. Percutaneous absorption of iodochlorhydroxyquin in humans. J Invest Dermatol. 1984 Feb;82(2):195-8. Abstract Full text (link to original source)
  5. Fischer T, Fagerlund C, Hartvig P. Absorption of 8-hydroxyquinolines through the human skin. Acta Derm Venereol. 1978;58(5):407-11. Abstract

Total visits

1,103

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM